For Sinopharm, China’s biggest vaccine developer, coronavirus offers a shot at a future that had been out of reach.
The state-backed company is betting that the urgent need to inoculate billions of people across the world will finally allow it to establish its credentials as a global supplier.
Its first Covid-19 vaccine was approved by Chinese authorities late last year, handing the company the lion’s share of a national immunisation programme that started in earnest in January. Its second was approved last month.
您已閱讀6%（517字），剩餘94%（7808字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。